Drug intelligence / Profile preview

DMOT4039A

Development stage: Phase 1
Lead developer: Genentech
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DMOT4039A is an investigational antibody-drug conjugate (ADC) designed for the treatment of cancers expressing mesothelin, such as pancreatic and ovarian cancer. It consists of a humanized IgG1 anti-mesothelin monoclonal antibody (h7D9.v3 or MMOT0530A) linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. The ADC targets mesothelin-expressing tumor cells, delivering MMAE directly to these cells to disrupt microtubules and induce cell death. Clinical studies have shown that DMOT4039A has antitumor activity and a tolerable safety profile in patients with unresectable pancreatic or platinum-resistant ovarian cancer[2][3][5][6].

Other names: h7D9.v3 (antibody component)MMOT0530A (antibody component)

Targets

TUBB (Tubulin (alpha and beta subunits))Mesothelin

Beyond the preview

Go deeper on DMOT4039A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMOT4039A.

Explore the full profile